Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study

Table 2 Correlation between ELABELA and study variables in all subjects

	r	P value
Age, years	− 0.300	< 0.001***
Male sex	0.007	0.932
Body mass index, kg/m²	0.158	0.074
Coronary heart disease	0.007	0.926
Diabetes Mellitus	− 0.016	0.840
Hyperlipidemia	0.107	0.174
Systolic blood pressure, mmHg	0.122	0.121
Diastolic blood pressure, mmHg	− 0.010	0.900
Mean arterial pressure, mmHg	0.052	0.513
Heart rate, bpm	− 0.156	0.047*
BNP, pg/ml	− 0.330	< 0.001***
Creatine, umol/l	− 0.134	0.110
Hemoglobin A1C, %	− 0.040	0.648
LDL-c, mmol/l	0.076	0.369
HDL-c, mmo/l	0.084	0.327
Total cholesterol, mmol/l	0.130	0.125
Homocysteine, umol/l	− 0.134	0.113
ESR, mm/h	− 0.073	0.417
Hs-CRP, mg/l	− 0.152	0.100
Troponin I, ng/ml	− 0.010	0.908
LAD, mm	− 0.289	0.001**
LVEDd, mm	0.003	0.976
LVEDs, mm	− 0.089	0.326
LVEF, mm	0.117	0.195
ACEI or ARB	0.096	0.223
Beta blocker	0.052	0.512
CCBs	− 0.046	0.560
Diuretics	− 0.068	0.390

BNP brain natriuretic peptide, LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, ESR erythrocyte sedimentation rate, hs-CRP high-sensitivity C-reactive protein, LAD left atrial diameter, LVEDd left ventricular end diastolic diameter, LVEDs left ventricular end systolic diameter, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor antagonists, CCBs Calcium channel blockers
^*P value less than 0.05; **P value less than 0.01; ***P value less than 0.001

ISSN: 1471-2261